HirnTumor Diskussionsforum
Behandlungsmöglichkeiten => Chemotherapie => Thema gestartet von: Ulrich am 06. August 2008, 13:55:28
-
http://www.brainlife.org/treatment/irinotecan.htm
Irinotecan (CPT-11)
http://de.wikipedia.org/wiki/Irinotecan
http://www.chemocare.com/bio/cpt.asp
Camptosar®
Camptothecin-11
-
http://neuro-oncology.dukejournals.org/cgi/content/abstract/15228517-2008-075v1
http://neuro-oncology.dukejournals.org/cgi/content/abstract/11/1/80
Experience with irinotecan for the treatment of malignant glioma
James J. Vredenburgh 1*, Annick Desjardins 2, David A. Reardon 2, Henry S. Friedman 2
Curr Opin Neurol. 2008 Dec;21(6):736-44.
Emerging antiangiogenic treatments for gliomas - efficacy and safety issues. (http://www.ncbi.nlm.nih.gov/pubmed/19060566?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum)
Dietrich J, Norden AD, Wen PY.
Division of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
Zitat:
SUMMARY: Antiangiogenic drugs have been shown to have promising activity in recurrent malignant gliomas. Investigation of novel antiangiogenic compounds and future clinical trials will determine whether these drugs have a role in first-line therapy. This article reviews the rationale for targeting angiogenesis in malignant brain tumors and summarizes the results of recent clinical trials. In addition, this review will outline potential toxicities associated with angiogenesis inhibition in an attempt to provide practical guidance to physicians treating patients with malignant gliomas.
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme (http://neuro-oncology.dukejournals.org/cgi/content/full/10/2/216?view=long&pmid=18314417)
Neuro Oncol 2008 10(2):216-222
Der Artikel ist kostenlos frei lesbar.
-
Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy (http://www.springerlink.com/content/ew1143814r04k355/)